ALC 📈 Alcon - Overview
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0432492467
ALC: Contact Lenses, Surgical Instruments, Intraocular Lenses, Eye Care Products
Alcon AG is a global leader in the eye care industry, dedicated to researching, developing, manufacturing, distributing, and selling a wide range of eye care products for eye care professionals and their patients worldwide. The company's product portfolio is divided into two main segments: Surgical and Vision Care. The Surgical segment offers a broad range of equipment, instrumentation, and diagnostics, including intraocular lenses, implantables, and consumables such as viscoelastics, surgical solutions, and incisional instruments. This segment also provides custom pak surgical procedure packs, which are designed to simplify and streamline surgical procedures.
The company's cataract products are a key part of its Surgical segment, and include advanced technologies such as the Centurion vision system, LenSx laser system, and ARGOS biometer. These products are designed to provide eye care professionals with the tools they need to perform complex cataract surgeries with precision and accuracy. Additionally, Alcon AG offers a range of vitreoretinal products, including constellation vision systems, procedure packs, lasers, and hand-held microsurgical instruments. These products are used to treat a variety of retinal conditions, including diabetic retinopathy and age-related macular degeneration.
Alcon AG's refractive surgery products are also an important part of its Surgical segment, and include the WaveLight lasers and Contoura Vision systems used for LASIK treatment. The company's implantable products, such as the AcrySof IQ products, are designed to correct presbyopia and astigmatism at the time of cataract surgery, providing patients with improved vision and reduced dependence on glasses or contact lenses. The EX-PRESS glaucoma filtration device is another key product in the company's Surgical segment, and is used to treat glaucoma by reducing intraocular pressure.
The Vision Care segment of Alcon AG provides a range of products designed to promote eye health and comfort, including daily disposable, reusable, and color-enhancing contact lenses. The company's ocular health products, such as dry eye treatments, glaucoma medications, and contact lens care solutions, are designed to help patients manage a variety of eye conditions and maintain good eye health. Alcon AG also offers ocular vitamins and redness relievers, which are designed to promote eye health and reduce the risk of eye problems.
With a history dating back to 1945, Alcon AG has established itself as a leader in the eye care industry, with a strong commitment to research and development, and a focus on providing high-quality products that meet the needs of eye care professionals and their patients. The company is headquartered in Geneva, Switzerland, and is listed on the SIX Swiss Exchange under the ticker symbol ALC. Its common stock is classified as a health care equipment stock, and is part of the GICS Sub Industry: Health Care Equipment.
Additional Sources for ALC Stock
ALC Stock Overview
Market Cap in USD | 43,501m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception |
ALC Stock Ratings
Growth 5y | 46.0% |
Fundamental | 48.4% |
Dividend | 43.8% |
Rel. Strength Industry | 590 |
Analysts | - |
Fair Price Momentum | 69.05 CHF |
Fair Price DCF | 38.92 CHF |
ALC Dividends
Dividend Yield 12m | 0.32% |
Yield on Cost 5y | 0.43% |
Annual Growth 5y | 2.53% |
Payout Consistency | 90.0% |
ALC Growth Ratios
Growth Correlation 3m | -89.9% |
Growth Correlation 12m | 65.5% |
Growth Correlation 5y | 69.9% |
CAGR 5y | 6.27% |
CAGR/Mean DD 5y | 0.58 |
Sharpe Ratio 12m | 0.57 |
Alpha | -3.35 |
Beta | 0.65 |
Volatility | 22.83% |
Current Volume | 1977.3k |
Average Volume 20d | 768.4k |
As of December 21, 2024, the stock is trading at CHF 76.02 with a total of 1,977,273 shares traded.
Over the past week, the price has changed by -1.04%, over one month by +0.21%, over three months by -8.77% and over the past year by +16.09%.
Partly, yes. Based on ValueRay Fundamental Analyses, Alcon (SW:ALC) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 48.42 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALC as of December 2024 is 69.05. This means that ALC is currently overvalued and has a potential downside of -9.17%.
Alcon has no consensus analysts rating.
According to ValueRays Forecast Model, ALC Alcon will be worth about 75.5 in December 2025. The stock is currently trading at 76.02. This means that the stock has a potential downside of -0.67%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 99 | 30.2% |
Analysts Target Price | - | - |
ValueRay Target Price | 75.5 | -0.7% |